Business Wire

RION Announces First Patient Dosed in Phase 2 Clinical Study of Purified Exosome Product™ for Diabetic Foot Ulcers

ROCHESTER, Minn.--(BUSINESS WIRE)--RION, a clinical-stage regenerative medicine company at the forefront of exosome therapeutics, announced today the first subject was dosed in the Phase 2 clinical ...
Business Wire

RION Announces Initiation of Phase 2A Clinical Study for Purified Exosome Product™ (PEP™) in Diabetic Foot Ulcers

RION's Phase 2A clinical trial focuses on evaluating the safety and efficacy of Platelet Exosome Product™ (PEP™) combined with TISSEEL fibrin sealant for treating Diabetic Foot Ulcers (DFU). Diabetic ...
Seeking Alpha

Capricor Therapeutics Announces First Subjects Dosed in Phase 1 Clinical Trial of Novel Exosome-Based Vaccine

SAN DIEGO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (CAPR) (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today ...
Morningstar

Neucore Bio Awarded U.S. National Institutes of Health (NIH) STTR Phase I Grant to Pursue Exosome-based Genetic Medicine for Charcot-Marie-Tooth Disease Type 1A (CMT1A)

Neucore Bio Awarded U.S. National Institutes of Health (NIH) STTR Phase I Grant to Pursue Exosome-based Genetic Medicine for Charcot-Marie-Tooth Disease Type 1A (CMT1A) Funded project aims to ...